Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Rituximab: a B-cell depletion therapy for dermatologic disease Prajapati V; Mydlarski PRSkin Therapy Lett 2007[Jul]; 12 (6): 6-9Rituximab (Rituxan, Genentech/ Biogen Idec) is a genetically engineered chimeric murine/human monoclonal antibody directed against CD20, a B lymphocyte-specific antigen. Initially approved for the treatment of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma (NHL), rituximab has been increasingly used to treat a variety of immune-mediated and autoimmune diseases. While anecdotal case reports recommend its "off-label" use in dermatology, randomized clinical trials are required to firmly establish the safety and efficacy of this emerging biologic therapy.|Antibodies, Monoclonal, Murine-Derived[MESH]|Antibodies, Monoclonal/adverse effects/pharmacology/*therapeutic use[MESH]|Autoimmune Diseases/drug therapy[MESH]|B-Lymphocytes/*immunology[MESH]|Humans[MESH]|Immunologic Factors/adverse effects/pharmacology/*therapeutic use[MESH]|Lymphocyte Depletion/*methods[MESH]|Lymphoma, B-Cell/drug therapy[MESH]|Rituximab[MESH]|Skin Diseases/*drug therapy[MESH]|Skin Neoplasms/drug therapy[MESH] |